The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1371
Rilpivirine (Edurant) - A New Drug for HIV Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved rilpivirine (Edurant – Janssen), a non-nucleoside reverse transcriptase inhibitor (NNRTI), for use with other antiretroviral agents for treatment of HIV-1 infection in treatment-naive adults. Rilpivirine is also available in a fixed-dose combination with emtricitabine and tenofovir (Complera – Gilead).

NNRTIs — All NNRTIs available in the US are listed in Table 1. Resistance to older NNRTIs (delavirdine, nevirapine and efavirenz) develops rapidly if they are used alone or in combinations that do not completely suppress viral replication. Cross resistance has been common among NNRTIs, with the exception of etravirine.1

CLINICAL STUDIES — FDA approval of rilpivirine was based on pooled 48-week results from 2 double-blind non-inferiority studies comparing its safety and efficacy with that of efavirenz in a ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rilpivirine (Edurant) - A New Drug for HIV Infection
Article code: 1371c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian